Worth reading
66In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Announced details
「バイオものづくり」生産性向上支援サービス
Applicable field (uses covered by this announcement)
バイオものづくり、バイオ医薬品、抗体医薬の生産性向上
Launch date2025年9月22日（サービス提供開始の発表。具体的な実施開始日はNot disclosed）
Contract Date2025年9月22日（契約締結の発表日。契約締結日そのものはNot disclosed）
Relationship between the counterparty and the company
Human Metabolome Technologies,Inc.6090
Relationship with the Company
抗体医薬の生産性向上に向けた取り組みの契約を締結した取引先。資本関係・人的関係はNot disclosed。
CounterpartyDAIICHI SANKYO COMPANY,LIMITED
本社：東京都中央区、代表取締役社長 兼 CEO：奥澤 宏幸。抗体医薬の研究開発を行っている。
Impact on Business Performance
The impact on our financial results is minor.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | 「バイオものづくり」生産性向上支援サービス |
| Counterparty | DAIICHI SANKYO COMPANY,LIMITED |
| Counterparty overview | 本社：東京都中央区、代表取締役社長 兼 CEO：奥澤 宏幸。抗体医薬の研究開発を行っている。 |
| Relationship with the Company | 抗体医薬の生産性向上に向けた取り組みの契約を締結した取引先。資本関係・人的関係はNot disclosed。 |
| Contract Date | 2025年9月22日（契約締結の発表日。契約締結日そのものはNot disclosed） |
| Launch date | 2025年9月22日（サービス提供開始の発表。具体的な実施開始日はNot disclosed） |
| Applicable area | バイオものづくり、バイオ医薬品、抗体医薬の生産性向上 |
| Impact on Business Performance | The impact on our financial results is minor. |
Items this document does not state (10)
Contract ValueOffering priceAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleQuantitative EffectsUsage historySource
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.第一三共が研究開発する複数の細胞株について、エネルギー代謝や物質のやり取りが期待どおりに機能しているかを比較検証し、細胞の増殖や抗体産生に影響する要因を明らかにするため。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.